The fellowship is awarded annually to early-career scientists whose research has led to new discoveries that improve people’s lives and enhance our understanding of the universe.
The lab helps reduce the time it takes fledgling biohealth companies to launch by six to nine months and is instrumental in keeping biohealth talent in Wisconsin.
The vaccine will target those most vulnerable to COVID-19 — namely, the elderly and those with health conditions that weaken their immune system. Phase 1 trials could begin in early 2021 and UW–Madison may be a trial site.
The research helps us understand how genes and hormones interact to develop male reproductive systems, a step toward researching why disorders in these organs have become more common and how we might prevent them.
The predictive tool is a boon for researchers studying how cells control the activity of genes, helping explain how cells achieve their key functions and how they go haywire, as happens in diseases such as cancer.
On Sept. 20, Professor Heidi Dvinge passed away unexpectedly. Her colleagues describe her tragic loss as “devastating.”
Researcher Jan Huisken’s vision is to redesign a high-end optical microscope — normally big enough to fill an entire room — down to the dimensions of a suitcase, with minimal loss of power or precision.
The Forward BIO Institute institute aims at making Wisconsin a Midwestern hub of the ongoing merger of pharmaceuticals, medical devices and cutting-edge tissue engineering.
UW-Madison scientists have shown that a recently-discovered variety of lignin, catechyl lignin (C-lignin), has attributes that could make it well-suited as the starting point for a range of bioproducts.
Often, in order to identify a fatty liver, an invasive liver biopsy is required. Taking a blood sample would be a much simpler way to diagnose it.
With countless tools and machines, the possibilities for bringing an idea to life are endless at the College of Engineering’s Technical…
Promising results in the lab and in animal models could set the stage for developing a treatment for Alexander disease, a rare and usually fatal neurological disease with no known cure.
Carl Ross has more than 26 years of experience advancing a wide range of cell and gene therapies, vaccines and therapeutic proteins into human clinical trials.